An interventional study of Performance of the Upper Limb (PUL) Test and Brook test in Duchenne Muscular Dystrophy (DMD), sponsored by Centre Hospitalier Universitaire de Liege. Not yet recruiting at 1 site in Belgium. Open to male participants. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium — 14 open to participants now, 20 under way, 6 of them phase 3. Muscular Dystrophy, Duchenne · Belgium.
Among the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, this one is the 36th largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 56th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →14 of the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Belgium, Australia, Canada and 7 more countries
Ages 7–16 · Men only
Centre Hospitalier Universitaire de Liege · Sites in Belgium
Ages 4 mo+
Entrada Therapeutics, Inc. · Sites in Belgium, Italy, Netherlands and 2 more countries
Ages 4–20 · Men only
Entrada Therapeutics, Inc. · Sites in Belgium, Italy, Spain and 1 more country
Ages 4–20 · Men only
Italfarmaco · Sites in Belgium, Italy, Netherlands and 1 more country
Ages 2–6 · Men only
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 26 · Phase 3 23 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 90 across the 52 interventional studies, 220 across the 3 observational. Of the 35 that completed or were terminated, 20 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 56 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Centre Hospitalier Universitaire de Liege has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
3 of the studies in Muscular Dystrophy, Duchenne with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06773988Universitaire Ziekenhuizen KU LeuvenFollow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Muscular Dystrophy, Duchenne with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the absence of dystrophin, leading to progressive muscle degeneration. Symptoms typically begin in early childhood and result in loss of ambulation by early adolescence, followed by cardiorespiratory complications. Although early treatment, including corticosteroids and emerging therapies, can slow disease progression, sensitive tools to monitor functional decline-particularly in non-ambulant patients-remain limited.
Current assessments rely primarily on clinical scales and hospital-based evaluations, which may not detect subtle changes or reflect real-life function. Digital outcome measures derived from wearable sensors offer a promising approach for continuous, objective monitoring in daily life. This study aims to evaluate the feasibility, reliability, clinical validity, and sensitivity of digital measures to assess upper limb function in non-ambulant patients with genetically confirmed DMD. The Syde device, previously validated in ambulant DMD patients, will be investigated for its applicability in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Performance of the Upper Limb (PUL) Test · Diagnostic Test: Brook test · Diagnostic Test: Dynamometric measurements of muscle strength · Diagnostic Test: Forced Vital Capacity (FVC) test · Diagnostic Test: Clinical Global Impression - Severity (CGI-S) · Diagnostic Test: Clinical Global Impression - Improvement (CGI-C) · Other: Patient Global Impression of severity (PGI-S) · Device: Syde
This test consists of a set of small manoeuvres (lifting a box, writing, etc.) designed to evaluate the upper-limb functionality of non-ambulatory patients. It was developed specifically for use in cases of Duchenne muscular dystrophy.
The Brooke Upper Extremity Functional Rating Scale will be used to assess the global functional level of upper limb involvement. This 6-point ordinal scale classifies patients according to their highest achievable upper limb function, from full arm abduction to absence of useful hand function.
Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.
Forced Vital Capacity (FVC) will be assessed using standardized spirometry procedures. The primary parameter will be FVC expressed as percentage of predicted values. At least three acceptable and reproducible maneuvers will be performed according to standard guidelines.
The CGI-S is a clinician-rated scale used at baseline to assess the overall severity of the participant's condition, based on all available clinical information. The rating reflects the clinician's judgment without standardized scoring rules and must be performed by a clinician experienced in Duchenne Muscular Dystrophy. The CGI-S evaluates three domains: physical motor function, respiratory function, and bulbar function. It is completed after all other study assessments (excluding patient-reported outcomes) to ensure a comprehensive evaluation.
The CGI-C is used at each follow-up visit to assess changes in the participant's condition relative to baseline. It provides a clinician-determined measure of improvement or worsening, based on overall clinical judgment rather than fixed criteria. Like the CGI-S, it covers physical motor, respiratory, and bulbar domains and is performed after all other study assessments (excluding patient-reported outcomes). The CGI-C is expected to track consistently with prior CGI-S evaluations, reflecting changes in disease status over time.
The PGI-S (Patient Global Impression of Severity) is a simple, validated, single-item self-administered scale used to assess the current severity of a patient's condition. Widely used in clinical trials, it allows patients to rate their condition, on a 4- to 6-point scale (from 'Normal' to 'Very severe').
Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Device usage (recording time)
Total recording time per recording period (hours)
Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Patient compliance (Min)
Percentage of participants achieving minimal threshold (expected 50h) of recording time per period
Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Patient compliance (Max)
Percentage of participants achieving optimal threshold (expected 180h) of recording time per period
Time frame: Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Reliability
Intraclass Correlation Coefficient (ICC) for two distinct consecutive half-periods
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24
Clinical validity of digital outcome vs Brooke
Correlation between digital outcome and Brooke Upper Extremity Rating Scale (Brooke score)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24
Clinical validity of digital outcome vs PUL
Correlation between digital outcome and Performance of Upper Limb (PUL) score
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24
Sensitivity of Digital Upper Limb Outcome Measures
Sensitivity will be evaluated by assessing the ability of digital outcome measures to detect change over time combining mean change from baseline, slope of change over time, and standardized response mean (SRM).
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2029, 35 months later.
Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 35 months is above that.
Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Centre Hospitalier Universitaire de Liege